Amanda Nickles Fader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amanda Nickles Fader has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Allison E. Axtell
3 shared publicationsDavid M. O'MAlley
3 shared publicationsKristine M. Zanotti
3 shared publicationsLaura J. Havrilesky
3 shared publicationsPaola A. Gehrig
3 shared publicationsPeter G. Rose
3 shared publications
Latest Publications
- 1 November 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 115 (2) , 244-248
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
- 1 November 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 115 (2) , 244-248
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
- 1 October 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (7) , 1281-1283
Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
- 1 October 2009
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (7) , 1281-1283
Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
- 1 May 2009
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 16 (3) , 333-339
Total Laparoscopic Hysterectomy versus Laparoscopic-Assisted Vaginal Hysterectomy in Endometrial Cancer: Surgical and Survival Outcomes
- 1 May 2009
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 16 (3) , 333-339
Total Laparoscopic Hysterectomy versus Laparoscopic-Assisted Vaginal Hysterectomy in Endometrial Cancer: Surgical and Survival Outcomes
Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
BACKGROUND: A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients.METHODS: A retrospective, multi‐institutional study of stage I UPSC patients diagnosed from 1993 to 2006 was performed. Patients underwent comprehensive surgical staging; postoperative treatment included observation (OBS); radiotherapy alone (RT); or platinum/taxane–based chemotherapy (CT) ± RT.RESULTS: The authors identified 142 patients with a median follow‐up of 37 months (range, 7‐144 months). Thirty‐three patients were observed, 20 received RT alone, and 89 received CT ± RT. Twenty‐five recurrences (17.6%) were diagnosed, and 60% were extrapelvic. Chemotherapy‐treated patients experienced significantly fewer recurrences than those treated without chemotherapy (P = .013). Specifically, CT ± RT patients had a lower risk of recurrence (11.2%) compared with patients who received RT alone (25%, P = .146) or OBS (30.3%, P = .016). This effect was most pronounced in stage IB/IC (P = .007). CT‐ and CT + RT–treated patients experienced similar recurrence. After multivariate analysis, treatment with chemotherapy was associated with a decreased risk of recurrence (P = .047). The majority of recurrences (88%) were not salvageable. Progression‐free survival (PFS) and cause‐specific survival (CSS) for chemotherapy‐treated patients were more favorable than for those who did not receive chemotherapy (P = .013 and .081). Five‐year PFS and CSS rates were 81.5% and 87.6% in CT ± RT, 64.1% and 59.5% in RT alone, and 64.7% and 70.2% for OBS.CONCLUSIONS: Stage I UPSC patients have significant risk for extrapelvic recurrence and poor survival. Recurrence and survival outcomes are improved in well‐staged patients treated with platinum/taxane–based chemotherapy. This multi‐institutional study is the largest to support systemic therapy for early stage UPSC patients. Cancer 2009. © 2009 American Cancer Society.
Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
BACKGROUND: A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients.METHODS: A retrospective, multi‐institutional study of stage I UPSC patients diagnosed from 1993 to 2006 was performed. Patients underwent comprehensive surgical staging; postoperative treatment included observation (OBS); radiotherapy alone (RT); or platinum/taxane–based chemotherapy (CT) ± RT.RESULTS: The authors identified 142 patients with a median follow‐up of 37 months (range, 7‐144 months). Thirty‐three patients were observed, 20 received RT alone, and 89 received CT ± RT. Twenty‐five recurrences (17.6%) were diagnosed, and 60% were extrapelvic. Chemotherapy‐treated patients experienced significantly fewer recurrences than those treated without chemotherapy (P = .013). Specifically, CT ± RT patients had a lower risk of recurrence (11.2%) compared with patients who received RT alone (25%, P = .146) or OBS (30.3%, P = .016). This effect was most pronounced in stage IB/IC (P = .007). CT‐ and CT + RT–treated patients experienced similar recurrence. After multivariate analysis, treatment with chemotherapy was associated with a decreased risk of recurrence (P = .047). The majority of recurrences (88%) were not salvageable. Progression‐free survival (PFS) and cause‐specific survival (CSS) for chemotherapy‐treated patients were more favorable than for those who did not receive chemotherapy (P = .013 and .081). Five‐year PFS and CSS rates were 81.5% and 87.6% in CT ± RT, 64.1% and 59.5% in RT alone, and 64.7% and 70.2% for OBS.CONCLUSIONS: Stage I UPSC patients have significant risk for extrapelvic recurrence and poor survival. Recurrence and survival outcomes are improved in well‐staged patients treated with platinum/taxane–based chemotherapy. This multi‐institutional study is the largest to support systemic therapy for early stage UPSC patients. Cancer 2009. © 2009 American Cancer Society.
- 1 March 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (3) , 558-562
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
- 1 March 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (3) , 558-562
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
- 1 April 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 109 (1) , 33-38
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
- 1 April 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 109 (1) , 33-38
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
- 1 February 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 109 (2) , 519-521
A 14-Week Abdominal Pregnancy After Total Abdominal Hysterectomy
Pregnancy after hysterectomy is rare. Because this clinical phenomenon is so uncommon, the diagnosis is not always considered in the evaluation of pain in a reproductive-aged woman after hysterectomy. Delay in diagnosis can result in potentially catastrophic intra-abdominal bleeding. A 31-year-old multigravida underwent a total abdominal hysterectomy for menometrorrhagia. She experienced several weeks of postoperative abdominal pain and ultimately was diagnosed with a 14-week size intra-abdominal pregnancy. Surgical evacuation of the fetus and products of conception were complicated by significant intra- operative bleeding. In reproductive-aged women undergoing hysterectomy, it is vital to obtain preoperative urine hCG levels immediately before surgery and to consider ectopic pregnancy in the differential diagnosis of these women when severe or persistent abdominal pain occurs postoperatively.
- 1 February 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 109 (2) , 519-521
A 14-Week Abdominal Pregnancy After Total Abdominal Hysterectomy
Pregnancy after hysterectomy is rare. Because this clinical phenomenon is so uncommon, the diagnosis is not always considered in the evaluation of pain in a reproductive-aged woman after hysterectomy. Delay in diagnosis can result in potentially catastrophic intra-abdominal bleeding. A 31-year-old multigravida underwent a total abdominal hysterectomy for menometrorrhagia. She experienced several weeks of postoperative abdominal pain and ultimately was diagnosed with a 14-week size intra-abdominal pregnancy. Surgical evacuation of the fetus and products of conception were complicated by significant intra- operative bleeding. In reproductive-aged women undergoing hysterectomy, it is vital to obtain preoperative urine hCG levels immediately before surgery and to consider ectopic pregnancy in the differential diagnosis of these women when severe or persistent abdominal pain occurs postoperatively.